Trials / NCT01233609
Trial of Oral Valproic Acid for Retinitis Pigmentosa
Completed Phase 2 Drug / neuroprotection
- Sponsor
- Foundation Fighting Blindness
- Treatment
- Valproic Acid; Placebo
- Gene
- Not stated
- Conditions
- Retinitis Pigmentosa
- Ages
- 18 Years to no upper limit
- Enrollment
- 90 participants
- Started
- 2010-11
- Main results expected
- 2015-12
- Results posted
- Yes
- Record last updated
- 2017-12-02
What the study is testing
The objectives of this study are to evaluate the efficacy of Valproic Acid (VPA) to both slow the progression of visual function loss and/or to restore visual function in patients with Autosomal Dominant Retinitis Pigmentosa (RP) and to collect safety and tolerability information.
Where it runs
United States (6)
- University of Miami, Bascom Palmer Eye Institute, Miami, Florida
- University of Michigan, Ann Arbor, Ann Arbor, Michigan
- Oregon Health & Science University, Portland, Oregon
- University of Tennessee, Hamilton Eye Institute, Memphis, Tennessee
- Retina Foundation of the Southwest, Dallas, Texas
- University of Utah School of Medicine, Moran Eye Center, Salt Lake City, Utah